Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.63 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7316113 | 1.00 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL21286088 | 1.00 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL23524375 | 0.98 | TAAR1 (0.61) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL13996924 | 0.81 | CYP1A2 (0.66) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL11162290 | 0.81 | SLC6A2 (0.55) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL178625 | 0.80 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL6077438 | 0.80 | SLC6A2 (0.54) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL10076448 | 0.80 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL765297 | 0.80 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL7343144 | 0.79 | SLC6A2 (0.59) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 717 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062772-A1 | PHASE CHANGE METAL ALLOYS AND THERMAL INTERFACE MATERIAL ASSEMBLY COMBINING A PATTERNED METAL FOIL WITH A PHASE CHANGE METAL ALLOY | THE INDIUM CORP OF AMERICA (US) | 2026-03-05 | — | — | US | claimed |
| EP-4124125-B1 | POWER-LIMIT REPORTING IN A COMMUNICATION SYSTEM USING CARRIER AGGREGATION | SUN PATENT TRUST (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250198980-A1 | COMBINATORIAL HIGH-THROUGHPUT SCREENING OF COMPLEX POLYMERIC ENZYME IMMOBILIZATION SUPPORTS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-06-19 | — | — | US | claimed |
| US-20250188521-A1 | NUCLEIC ACID DELIVERY SCAFFOLDS | Singular Genomics Systems, Inc. | 2025-06-12 | — | — | US | claimed |
| CN-120090672-A | MIMO open loop uplink precoding optimization system for gigabit transmission | 中国人民解放军军事科学院战争研究院 | 2025-06-03 | — | — | CN | claimed |
| CN-119963082-A | Emergency allocation method for engineering materials in complex difficult region | 北京交通大学 | 2025-05-09 | — | — | CN | claimed |
| CN-119896730-A | Double immunocyte adapter | 雷维托普有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119892806-A | Intercommunication system and method for special condition treatment of expressway | 中远海运科技股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2025072355-A1 | METHODS FOR AND COMPOSITIONS OF NON-PEG BIOCONJUGATES WITH ULTRA-HIGH DRUG-TO-AGENT RATIO | BIOHYBRID SOLUTIONS HOLDINGS, INC. (US) | 2025-04-03 | — | — | WO | claimed |
| CN-119652440-A | PCMA signal identification method based on joint probability density distribution | 中国电子科技集团公司第五十四研究所 | 2025-03-18 | — | — | CN | claimed |
| CN-114422016-A | PCMA signal identification method | 成都爱科特科技发展有限公司 | 2022-04-29 | — | — | CN | claimed |
| EP-3986922-A2 | TGF-BETA RECEPTORS AND METHODS OF USE | Kite Pharma, Inc. (US) | 2022-04-27 | — | — | EP | claimed |
| CN-114391021-A | TGF-beta receptors and methods of use | 凯德药业股份有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-112087253-B | Satellite simulator for asymmetric PCMA (Primary packet Access) | 中国卫通集团股份有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-11292986-B2 | Mechanochemical resistant intramolecular crosslinked polymers and uses thereof | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2022-04-05 | — | — | US | claimed |
| CN-114285945-A | Video interaction method and device and storage medium | 天翼爱音乐文化科技有限公司 | 2022-04-05 | — | — | CN | claimed |
| CN-114268612-A | Websocket-based webpage real-time voice communication method | 中电福富信息科技有限公司 | 2022-04-01 | — | — | CN | claimed |
| CN-112388199-B | Method, application and instrument for estimating welding performance of steel containing titanium and niobium elements | 首钢集团有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-114212851-A | Solar seawater desalination material based on natural plant rods and preparation method and application thereof | 中国科学院化学研究所 | 2022-03-22 | — | — | CN | claimed |
| CN-108985327-B | Terrain matching area self-organization optimization classification method based on factor analysis | 东南大学 | 2022-02-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062772-A1 | PHASE CHANGE METAL ALLOYS AND THERMAL INTERFACE MATERIAL ASSEMBLY COMBINING A PATTERNED METAL FOIL WITH A PHASE CHANGE METAL ALLOY | AP3M1, AP2A1, AP1M1 | TAAR1 3319/4885SLC18A2 2280/4885SIGMAR1 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.